The overall goal of the Animal and Therapeutics Core (Core B) is to provide centralized and standardized procedures for the animal studies to test the efficacy of therapeutic agents proposed in each of Projects 1-4. The Core will provide two of the most commonly used murine lung fibrosis models: (1) Bleomycin-induced pulmonary fibrosis model;and (2) AdTGF- B1[223/225]-induced lung fibrosis model. The Core will also provide standardized drug delivery service through 3 different routes for 3 different candidate drugs for 4 Projects: (1) airway/non-surgical intratracheal delivery of ncRNAs (miRs and siRNAs) for Projects 3, 4;(2) systemic/oral administration (gavage) of an orally effective small molecule Src kinase inhibitor AZD0530 for Project 2;(3) intra-pleural delivery of ncRNAs and the small molecule Src kinase inhibitor for Project 1. The Core leader Dr. Rui-Ming Liu and several Project leaders have extensive experience with these animal models and with the techniques used for the drug delivery proposed. To provide the standardized service to all the projects, the Core will 1) Coordinate purchase, health services, and care for experimental animals;2) Provide logistical and technical support in ensuring that experimental regimens are implemented correctly;3) Prepare and determine the titers of the adenovirus that expresses constitutively active TGF-B1 (AdTGF- B1[223/225] );4) Conduct intranasal (for AdTGF- B1[223/225] and intratracheal (for bleomycin) instillation to induce lung fibrosis for all Projects;5) Administrate the therapeutic drugs through gavage, non-surgical intratracheal instillation, and intrapleural instillation daily or every other day as designed in each Project;6) Monitor and record abnormal responses in animals during experimental periods and euthanize animal if necessary. Centralization of these animal models and treatment procedures in the Core B will facilitate the work of the Principle Investigators of each Project and ensure that experiments with each Project will be performed using identical and standardized methods for animal handling. Centralization of these services therefore will allow for fewer total numbers of animals to be utilized (cost-effective) and for the comparison ofthe results between different drugs and different administration routes ofthe same drug.
The overall goal ofthe Core B is to provide centralized and standardized procedures for the animal studies to test the efficacies of the potential therapeutic drugs proposed in 4 Projects in this Translational Project Program (T-PPG). The results from these studies may lead to the development of novel therapeutics for the treatment of Idiopathic Pulmonary Fibrosis, a devastating disease with no effective treatment.
|Bernard, Karen; Logsdon, Naomi J; Miguel, Veronica et al. (2017) NADPH Oxidase 4 (Nox4) Suppresses Mitochondrial Biogenesis and Bioenergetics in Lung Fibroblasts via a Nuclear Factor Erythroid-derived 2-like 2 (Nrf2)-dependent Pathway. J Biol Chem 292:3029-3038|
|Li, Fu Jun; Surolia, Ranu; Li, Huashi et al. (2017) Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. J Immunol 199:1596-1605|
|Ge, Jing; Cui, Huachun; Xie, Na et al. (2017) Glutaminolysis Promotes Collagen Translation and Stability via ?-ketoglutarate Mediated mTOR Activation and Proline Hydroxylation. Am J Respir Cell Mol Biol :|
|Cui, Huachun; Ge, Jing; Xie, Na et al. (2017) miR-34a promotes fibrosis in aged lungs by inducing alveolarepithelial dysfunctions. Am J Physiol Lung Cell Mol Physiol 312:L415-L424|
|Hough, K P; Chanda, D; Duncan, S R et al. (2017) Exosomes in immunoregulation of chronic lung diseases. Allergy 72:534-544|
|Sanders, Yan Y; Liu, Hui; Scruggs, Anne M et al. (2017) Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts. Am J Respir Cell Mol Biol 56:50-61|
|Cui, Huachun; Ge, Jing; Xie, Na et al. (2017) miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence. Am J Respir Cell Mol Biol 56:168-178|
|de Andrade, Joao A; Luckhardt, Tracy (2017) What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike! Am J Respir Crit Care Med 195:10-12|
|Xie, Na; Cui, Huachun; Ge, Jing et al. (2017) Metabolic characterization and RNA profiling reveal glycolytic dependence of profibrotic phenotype of alveolar macrophages in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 313:L834-L844|
|Surolia, Ranu; Li, Fu Jun; Wang, Zheng et al. (2017) 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight 2:e91377|
Showing the most recent 10 out of 60 publications